# Phreesia Inc. (PHR) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Providers & Services. Price $10.94, market value $679 million.

## Valuation
- **P/E (trailing): 60.8×** (5-yr avg 335.8×, 3-yr avg 335.8×). Phreesia Inc. trades at 60.8× trailing earnings, well below its own five-year average of 335.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 6.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.07**. A PEG of 0.07 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.4×**. Each dollar of revenue is priced at 1.4×.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.2×**. Enterprise value is 12.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 11.9%** (5-yr avg -0.8%). Free cash flow equals 11.9% of the market value, above its five-year average of -0.8%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 1.6%**. The inverse of the P/E: 1.6% of the price is earned each year.

## Profitability
- **Operating margin: 2.5%**. 2.5% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 0.5%**. 0.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 0.7%**. 0.7% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 3.7%**. Return on all capital, debt included, is 3.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.6%**. Each dollar of assets produces 1.6% of profit.

## Growth
- **Revenue growth (1 yr): 14.0%** (3-yr 18.5%/yr, 5-yr 25.8%/yr). Revenue grew 14.0% over the last year, against 25.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 103.9%**. Earnings per share rose 103.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Phreesia Inc. holds more cash than debt.
- **Altman Z-score: 2.63**. A Z-score of 2.63 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Phreesia Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (17 analysts). 17 analysts cover Phreesia Inc.; the consensus is buy, with an average price target of $14.00 (+28% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -64.9%** (YTD -35.3%, 3-mo 14.7%). The shares are down 64.9% over twelve months including dividends.
- **From 52-week high: -59.6%** (40.8% above the low). Trading 60% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 0.41** (volatility 59%). Beta of 0.41 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PHR · Page: https://foliofundamentals.com/stocks/phr

Not investment advice.